Siemens Healthcare Diagnostics has received CE-marking in Europe for the ADVIA Centaur® free PSA test, completing a full menu of tests that aid in prostate cancer detection and management.
The assays include prostate-specific antigen (PSA), complexed PSA (cPSA) and free PSA (fPSA), all available on both the Siemens ADVIA Centaur and the ADVIA Centaur XP® System. The new fPSA test, when used with the PSA test to calculate the percent free PSA value, can aid in discriminating between prostate cancer and benign prostatic disease which may help reduce unnecessary biopsies for patients.
Siemens new free PSA test is intended to be used in conjunction with the ADVIA Centaur PSA test to determine the percent free PSA value in men aged 50 years or older with total PSA values between 4 and 10 ng/mL and digital rectal exam (DRE) results non-suspicious for cancer. The percent free PSA value can be used to help discriminate between prostate cancer and benign prostatic disease. Prostate biopsy is required for the diagnosis of prostate cancer.
“Providing complete PSA diagnostic testing on one system offers a real advantage to both patients and laboratories,” said David Hickey, Executive Vice President, Central Laboratory and Global Research and Development, Siemens Healthcare Diagnostics. “Laboratories have more diagnostic options for their patients, which can enhance quality of care. At the same time, tests can be run more efficiently and cost effectively on a single instrument.”
The ADVIA Centaur free PSA assay allows laboratory professionals to consolidate PSA testing on a fully-automated, high-throughput immunoassay system. The comprehensive ADVIA Centaur PSA menu also includes cPSA, an alternative frontline test to aid in the detection of prostate cancer. Complexed PSA is a test that offers the advantage of higher specificity than total PSA as an aid in prostate cancer detection and management.1,2
The ADVIA Centaur free PSA assay is now available for sale on the ADVIA Centaur and Centaur XP® systems in Europe and Australia. For more information about Siemens portfolio of PSA prostate cancer detection assays, visit here.
The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare.
By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2009 (to September 30), the Sector posted revenue of 11.9 billion euros and profit of around 1.5 billion euros. For further information please visit: www.siemens.com/healthcare.
1. Babaian RJ, Naya Y, Chei C. Fritsche HA. The detection and potential economic value of complexed prostate specific antigen as a first-line test. J Urol 2006.
2. Partin AW, Brawer MK. Bartsch G. et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003 November: 170(5): 1787-91.
Source
Siemens Healthcare Diagnostics
www.medicalnewstoday.com
